Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06171685 | MMRC Horizon One: RRMM (MMRC-099) | active not recruiting | Phase 2 | 300 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03960840 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | active not recruiting | Phase 1 / Phase 2 | 217 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 4, 2026 | clinicaltrials |
| NCT04722172 |
| A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL |
| active not recruiting |
| Phase 2 |
| 55 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Jun 4, 2026 |
| clinicaltrials |
| NCT04974216 | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | active not recruiting | Phase 2 | 71 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jun 4, 2026 | clinicaltrials |
| NCT04984837 | Study of Lacutamab in Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 49 | The Lymphoma Academic Research OrganisationOTHER | 4 | Jun 4, 2026 | clinicaltrials |
| NCT05651178 | Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients | active not recruiting | Early Phase 1 | 10 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06282978 | Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes | active not recruiting | Phase 2 | 50 | PETHEMA FoundationOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT01415752 | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 373 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 3, 2026 | clinicaltrials |
| NCT02450708 | Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes | active not recruiting | N/A | 511 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04054167 | Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04430894 | KRDI in Transplant-Eligible MM | active not recruiting | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05162976 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | active not recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05850286 | A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities | active not recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT00544115 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | active not recruiting | Phase 2 | 260 | City of Hope Medical CenterOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT01046825 | Mature B-Cell Lymphoma And Leukemia Study III | active not recruiting | Phase 2 / Phase 3 | 128 | St. Jude Children's Research HospitalOTHER | 3 | Jun 2, 2026 | clinicaltrials |
| NCT04128748 | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | active not recruiting | Phase 3 | 635 | Acerta Pharma BVINDUSTRY | 27 | Jun 1, 2026 | clinicaltrials |
| NCT03319901 | Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL | active not recruiting | Phase 1 / Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04739813 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | active not recruiting | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05412290 | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05434689 | COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide(COMMANDER) | active not recruiting | Phase 1 / Phase 2 | 80 | University of Alabama at BirminghamOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06400251 | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | active not recruiting | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03157323 | Low GI Diet in Children and Adolescents With ALL | active not recruiting | N/A | 88 | Columbia UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03290950 | A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06092879 | Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France(ASSURE-3) | active not recruiting | — | 201 | Novartis PharmaceuticalsINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06445907 | Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT01840566 | High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT02275533 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | May 28, 2026 | clinicaltrials |
| NCT05157971 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05734495 | Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06357988 | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06360575 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06400238 | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT01351896 | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT02159755 | Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma | active not recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT04439149 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT04439188 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT06566547 | GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 2 | 116 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT00846742 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma | active not recruiting | Phase 2 | 88 | St. Jude Children's Research HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00734877 | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma(TT4B) | active not recruiting | Phase 3 | 382 | University of ArkansasOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT00869232 | UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | active not recruiting | Phase 2 | 90 | University of ArkansasOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01628029 | Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer | active not recruiting | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02427620 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 131 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | active not recruiting | Phase 1 | 153 | Institut de Recherches Internationales ServierOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT03035604 | Comprehensive Nutritional Geriatric Assessments in Identifying Malnutrition in Older Cancer Participants | active not recruiting | — | 180 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 5, 2026source: clinicaltrials